ImpediMed Surges with Record Revenue and SOZO Pro US Expansion

Strong Financial Performance Despite Currency Headwinds

ImpediMed Limited has delivered a record quarterly revenue of A$3.6 million for the first quarter of fiscal 2026, marking a 9% increase compared to the previous year. This growth was achieved despite the headwind of a stronger Australian dollar, which tempered the reported figures. The company’s Annual Recurring Revenue (ARR) also edged higher to A$14.4 million, reflecting the solid subscription-based model underpinning its SOZO Digital Health Platform.

Expanding US Footprint with Strategic Hospital Partnerships

With over 600 SOZO units now installed in prominent US medical centres such as the Mayo Clinic and Cleveland Clinic, ImpediMed is deepening its presence in a critical market. The signing of Master Services Agreements with 27 major Integrated Delivery Networks (IDNs) streamlines IT approvals and paves the way for rapid deployment of an additional 1,400 units focused on breast cancer-related lymphoedema (BCRL) detection. However, the quarter saw a slight dip in US unit sales to 26 from 44 in the prior quarter, attributed to delays in hospital approvals rather than demand.

SOZO Pro Launch Targets Heart Failure Market

The introduction of SOZO Pro, the only FDA-cleared bioimpedance spectroscopy device compatible with cardiac implantable devices, marks a significant strategic expansion. Commercial pilots are underway in the US, with encouraging feedback from cardiologists. This new platform leverages existing infrastructure and positions ImpediMed to tap into the growing heart failure and body composition monitoring markets, which are also benefiting from trends such as GLP-1 driven weight management.

Cash Flow and Cost Discipline

Operating cash outflows for the quarter stood at A$5.6 million, influenced by a one-off payment of A$1.1 million for long lead electronic components. Staff costs remained the largest expense at A$4.9 million, slightly down from the previous quarter. The company maintains a strong cash position with A$23 million on hand, including US$5 million drawn from a debt facility. In line with financial discipline, the Board has reduced director fees and continues to focus on cost control to reach cash flow break-even.

Reimbursement Gains Bolster Market Access

Reimbursement coverage in the US has accelerated, with 42 states now offering over 80% coverage for bioimpedance spectroscopy, up from 25 states last quarter. Coverage above 90% has also increased significantly, supporting the company’s sales ambitions. Recent policy updates from major payors, including Blue Cross Blue Shield plans, further validate the clinical and economic value of ImpediMed’s technology.

Investor Engagement and Outlook

ImpediMed has launched a dedicated Investor Hub to enhance transparency and communication with shareholders, reflecting a commitment to engagement as the company scales. While the near-term sales momentum in the US faces some operational hurdles, the combination of strong clinical demand, expanding reimbursement, and new product launches positions ImpediMed for continued growth in the digital health space.